This page uses content from Wikipedia and is licensed under CC BY-SA.

Talipexole

Talipexole
Talipexole.svg
Talipexole-3D-balls.png
Clinical data
Trade namesDomin
Other namesAlefexole
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H15N3S
Molar mass209.31 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996.[1] As of December 2014 it was not approved for marketing in the US nor in Europe.[2]

Talipexole is a D2 dopamine receptor agonist and interacts both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.[3]

The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints.[3] In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.[4]:15

References

  1. ^ PharmaLetter 22 July 1996 First Launch In Japan For Talipexole
  2. ^ EvaluatePharma Database. Page accessed 9 December 2014
  3. ^ a b Benkert O, Müller-Siecheneder F, Wetzel H. "Dopamine agonists in schizophrenia: a review". European Neuropsychopharmacology. 5 Suppl: 43–53. PMID 8775758.
  4. ^ Japanese Ministry of Health, Labour and Welfare March 2008 Pharmaceuticals and Medical Devices Safety Information No. 245